Dosage ; 7.5-22.5mg daily in 2-3 divided doses or single dose of 15mg nocte.
The dose is halved in elderly.
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Tranxene | Roche | Roche Products | 5mg | 30 | Tablet | per tablet | KES 179 |
| Tranxene | Roche | Roche Products | 10mg | 30 | Tablet | per tablet | KES 296 |
|
Clorazepate More info |
|
|---|---|
| Mode Of Action | Potentiation of the effect of gamma-amino butyrate (GABA). Example: diazepam, |
| Drug Indication | Short term use in anxiety and alcohol withdrawal |
| Dosage | 7.5-22.5mg daily in 2-3 divided doses or single dose of 15mg nocte. The dose is halved in elderly. |
| Drug Category | DRUGS ACTING ON CNS |
| Drug Sub-Category | Hypnotics, sedatives & tranquilizers
Specific Dosages Dosing: Adult Anxiety: Oral: 7.5-15 mg 2-4 times/day Ethanol withdrawal: Oral: Initial: 30 mg, then 15 mg 2-4 times/day on first day; maximum daily dose: 90 mg; gradually decrease dose over subsequent days. Seizures (anticonvulsant): Oral: Initial: Up to 7.5 mg/dose 2-3 times/day; increase dose by 7.5 mg at weekly intervals; not to exceed 90 mg/day Dosing: Pediatric (For additional information see "Clorazepate: Pediatric drug information") Seizures (anticonvulsant): Oral: Children 9-12 years: Initial: 3.75-7.5 mg/dose twice daily; increase dose by 3.75 mg at weekly intervals, not to exceed 60 mg/day in 2-3 divided doses. Children >12 years: Refer to adult dosing. Dosing: Geriatric Oral: Anxiety: 7.5 mg 1-2 times/day; use is not recommended in the elderly. Dosage Forms: U.S. Excipient information presented when available (limited, particularly for generics); consult specific product labeling. Tablet, oral, as dipotassium: 3.75 mg, 7.5 mg, 15 mg Tranxene® T-Tab®: 3.75 mg, 7.5 mg, 15 mg [scored] Generic Equivalent Available: U.S. Yes Use Treatment of generalized anxiety disorder; management of ethanol withdrawal; adjunct anticonvulsant in management of partial seizures Adverse Reactions Significant Frequency not defined. |